Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769738 | 0.94 | HDAC1 (0.39) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL21769881 | 0.93 | ALDH1A1 (0.39) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL21769572 | 0.91 | POLB (0.38) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL21769855 | 0.91 | MEN1 (0.39) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL21769743 | 0.90 | HDAC1 (0.38) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL17923453 | 0.90 | MAPT (0.35) | L3MBTL1ALDH1A1MAPTTP53MEN1 | |
| SCHEMBL2237688 | 0.90 | HDAC1 (0.39) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL3557373 | 0.88 | MAPT (0.36) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL2239362 | 0.88 | HDAC1 (0.38) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL21769877 | 0.88 | MAPT (0.41) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2263671-B1 | AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC (JP) | 2016-07-20 | — | — | EP | claimed |
| US-9050326-B2 | Amido derivatives-contained pharmaceutical composition | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | claimed |
| EP-2263671-A1 | AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2010-12-22 | — | — | EP | claimed |
| US-20090270463-A1 | AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | claimed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | claimed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | claimed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | claimed |
| WO-2020038812-A1 | NEW PROCESS FOR THE PREPARATION OF AMENAMEVIR | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-02-27 | — | — | WO | disclosed |
| EP-2263671-B1 | AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9050326-B2 | Amido derivatives-contained pharmaceutical composition | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2351565-A1 | MEDICINE FOR PREVENTING OR TREATING PAIN RELATED TO HERPES ZOSTER | Astellas Pharma Inc. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2263671-A1 | AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-1844775-A1 | THERAPEUTIC AGENT FOR HERPES PROGENITALIS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844776-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060229295-A1 | Amide derivatives | ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270463-A1 | AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION | ACMSD, ADM2, PAM | HDAC1 968/4885HDAC8 731/4885HDAC6 263/4885 |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | TPMT, RPL35, TYMP | HDAC1 39/4885HDAC8 32/4885HDAC6 1368/4885 |
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | GAP43, TRPV1, ACHE | HDAC1 1277/4885HDAC8 1199/4885HDAC6 771/4885 |
| US-20060229295-A1 | Amide derivatives | VAC14, HDAC8, ZC3HAV1 | HDAC1 7/4885HDAC8 2/4885HDAC6 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.